跳至主要内容
临床试验/EUCTR2014-000298-37-BE
EUCTR2014-000298-37-BE
进行中(未招募)
1 期

ear-Infrared fluorescence imaging during neck dissection in head and neck cancer patients after peritumoral injection of Indocyanine Green (a feasibility study)

Jules Borde Institute0 个研究点2014年9月25日

概览

阶段
1 期
干预措施
未指定
疾病 / 适应症
Imaging of lymph nodes to be resected in headand neck cancers
发起方
Jules Borde Institute
状态
进行中(未招募)
最后更新
9年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2014年9月25日
结束日期
待定
最后更新
9年前
研究类型
Interventional clinical trial of medicinal product
性别
All

研究者

发起方
Jules Borde Institute

入排标准

入选标准

  • \- All patients requiring neck dissection with resection of the primary (the decision and the type of neck dissection are preliminary decided during head and neck multidisciplinary oncologic consultation).
  • \- Informed consent form signed.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 10
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

排除标准

  • \- Age less than18 years old.
  • \- Inability to give informed consent.
  • \- History of allergy or hypersensitivity against the investigational product (its active substance or ingredients), to iodine or to shellfish.
  • \- Apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal or disseminated autonomies of the thyroid gland.
  • \- Documented coronary disease.
  • \- Advanced renal impairment (creatinine \> 1,5mg/dl).
  • \- During the 2 weeks before the enrolment, concurrent medication which reduces or increases the extinction of ICG (i.e. anticonvulsants, haloperidol and heparin).
  • \- Pregnancy, breastfeeding

结局指标

主要结局

未指定

相似试验